The New England journal of medicine
-
Randomized Controlled Trial Comparative Study
Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
Insulin icodec is an investigational once-weekly basal insulin analogue for diabetes management. ⋯ Glycemic control was significantly better with once-weekly insulin icodec than with once-daily insulin glargine U100. (Funded by Novo Nordisk; ONWARDS 1 ClinicalTrials.gov number, NCT04460885.).
-
Randomized Controlled Trial Comparative Study
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. ⋯ A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
-
Comment Letter
Case 14-2023: A Man with Redness of the Right Eye. Reply.